No Data
No Data
No Data
No Data
No Data
Y-mAbs Therapeutics (NASDAQ:YMAB) Rises 9.6% This Week, Taking One-year Gains to 161%
Yahoo FinanceApr 18 21:09
Little Excitement Around Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues
With a price-to-sales (or "P/S") ratio of 7.8x Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) may be sending bullish signals at the moment, given that almost half of all the Biotechs companies in the United
Simply Wall StApr 18 18:57
Y-mAbs Therapeutics Down Nearly 11%, on Pace for Largest Percent Decrease Since November 2022 -- Data Talk
Y-mAbs Therapeutics, Inc. (YMAB) is currently at $14.42, down $1.77 or 10.93% --Would be lowest close since March 18, 2024, when it closed at $13.76 --On pace for largest percent decrease since Nov.
Dow JonesApr 3 02:04
Selling US$1.9m Of Stock Was Lucrative Decision For Y-mAbs Therapeutics Insiders
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) stock rose 10% last week, but insiders who sold US$1.9m worth of stock over the last year are probably in a more advantageous position. Selling at an average
Simply Wall StMar 24 22:32
Y-Mabs Therapeutics CFO Resigns, Ensures Smooth Transition
TipRanksMar 14 21:33
Y-mAbs Therapeutics Has Commenced a Search Process for a Successor >YMAB
Y-mAbs Therapeutics Has Commenced a Search Process for a Successor >YMAB
Dow JonesMar 14 21:06
No Data
No Data